摘要
目的比较BRCA1、ERCC1、TUBB3、PRR13基因mRNA表达在初治和复发性卵巢上皮癌组织中的表达水平的差异,初步探讨该4种耐药相关基因与卵巢癌获得性耐药的关系。方法采用荧光定量PCR方法检测46例原发性卵巢上皮癌和14例复发性卵巢上皮癌组织标本中BRCA1、ERCC1、TUBB3、PRR13基因mRNA表达水平。结果结果发现BRCA1、ERCC1、TUBB3和PRR13mRNA的相对表达量对数在原发性卵巢癌和复发性卵巢中分别为-0.703±2.627和-0.966±2.582(P=0.742);-2.263±2.708和-2.657±2.718(P=0.636);1.760±1.431和2.038±1.752(P=0.549);-0.175±2.781和-1.152±2.495(P=0.244),均无统计学意义。结论复发性卵巢癌与原发性卵巢癌相比,未出现BRCA1、ERCC1、TUBB3和PRR13基因mRNA表达的改变。推测卵巢癌获得性耐药的发生可能为多途径/多因素/多基因参与的更复杂过程有关。
Objective To evaluate BRCA1, ERCC1, TUBB3 and PRR13 mRNA expression levels in primary and recurrent epithelial ovarian cancer tissues and to explore the relationship between these drug resistance genes and acquired drug resistance of ovarian cancer. Methods Totally 46 primary epithelial ovarian and 14 recurrent epithelial ovarian tumor samples were collected from the patients who received cytoreductive surgery. Real-time quantitative PCR was used to ana- lyze the mRNA expression of BRCA1, ERCC1, TUBB3 and PRR13 in those patients. Results BRCA1, ERCC1, TUBB3 and PRR13 mRNA relative expression logarithm in the primary and recurrent ovarian cancer patients was -0. 703 ±2. 627 and-0.966±2.582 （P=0.742）, -2.263 ±2.708 and-2.657±2.718 （P=0.636）, 1.760±1.431 and 2. 038 ± 1. 752 （P =0. 549）, -0. 175 ±2. 781 and - 1. 152 ±2. 495 （P =0. 244）, respectively. All the 4 drug resistance gene expression between the two groups had no significant difference. Conclusion There is no mRNA expression changes of BRCA1, ERCC1, TUBB3 and PRR13 genes between primary and recurrent ovarian cancers. Acquired drug resistance may be a nmlti-channel, muhi-factor and complicated process involving nmch more genes.
出处
《癌症进展》
2011年第5期573-576,共4页
Oncology Progress
关键词
复发性卵巢癌
获得性耐药
recurrent ovarian cancer acquired drug resistance
